Literature DB >> 22678525

Comparison between serum free triiodothyronine levels and body fluid distribution in hemodialysis patients.

Osamu Saito1, Takako Saito, Koshi Ueno, Takeshi Shiraishi, Takanori Kikuchi, Hisashi Yamamoto, Tetsu Akimoto, Yasuhiro Ando, Shigeaki Muto, Eiji Kusano.   

Abstract

AIM: Low free triiodothyronine (fT3) has been associated with the presence of malnutrition-inflammation syndrome in patients with end-stage renal disease (ESRD) and decreased overall survival in ESRD. Since thyroid hormone has a particular effect on body fluid status, we hypothesized that hemodialysis patients with low-T3 syndrome might have interstitial edema. In this study, we examined the relationship between levels of thyroid hormone and body composition parameters in Japanese hemodialysis patients.
METHODS: The subjects were 52 patients on maintenance hemodialysis. Serum levels of thyroid hormone and atrial natriuretic peptide (hANP) were measured. Body composition parameters were measured using a bioimpedance body composition analyzer.
RESULTS: Serum fT3 had positive correlations with body mass index (BMI), body fat mass (BFM), total body water (TBW) and intracellular water (ICW), and negative correlations with the ratio of extracellular water to total body water (ECW/TBW) and hANP. There were no correlations between serum fT4 and any body composition parameter. The 49 patients with data at baseline and after 1 year were divided into groups with increased (n = 33) and decreased (n = 16) fT3 after 1 year. ΔBMI and ΔBFM were significantly lower and ΔTBW, ΔICW, ΔECW and ΔECW/TBW (changes over 1 year from baseline) were significantly higher in patients with decreased fT3 compared to those with increased fT3. There was no significant difference in ΔhANP or Δcardiothoracic ratio between the two groups.
CONCLUSION: These results show that a decrease in fT3 might be associated with emaciation and interstitial edema in Japanese hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678525     DOI: 10.1007/s10157-012-0648-9

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  24 in total

1.  A systematic evaluation of bioelectrical impedance measurement after hemodialysis session.

Authors:  Biagio R Di Iorio; Luca Scalfi; Vincenzo Terracciano; Vincenzo Bellizzi
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

2.  Assessment of total body water from anthropometry-based equations using bioelectrical impedance as reference in Korean adult control and haemodialysis subjects.

Authors:  S W Lee; J H Song; G A Kim; K J Lee; M J Kim
Journal:  Nephrol Dial Transplant       Date:  2001-01       Impact factor: 5.992

3.  Low triiodothyronine and survival in end-stage renal disease.

Authors:  C Zoccali; F Mallamaci; G Tripepi; S Cutrupi; P Pizzini
Journal:  Kidney Int       Date:  2006-06-14       Impact factor: 10.612

4.  Multifrequency bioelectrical impedance estimates the distribution of body water.

Authors:  K Cha; G M Chertow; J Gonzalez; J M Lazarus; D W Wilmore
Journal:  J Appl Physiol (1985)       Date:  1995-10

5.  Bioimpedance resistance ratios for the evaluation of dry weight in hemodialysis.

Authors:  D M Spiegel; K Bashir; B Fisch
Journal:  Clin Nephrol       Date:  2000-02       Impact factor: 0.975

6.  Blood volumes and renal function in overt and subclinical primary hypothyroidism.

Authors:  C Villabona; M Sahun; M Roca; J Mora; N Gómez; J M Gómez; R Puchal; J Soler
Journal:  Am J Med Sci       Date:  1999-10       Impact factor: 2.378

7.  Low triiodothyronine: a new facet of inflammation in end-stage renal disease.

Authors:  Carmine Zoccali; Giovanni Tripepi; Sebastiano Cutrupi; Patrizia Pizzini; Francesca Mallamaci
Journal:  J Am Soc Nephrol       Date:  2005-07-20       Impact factor: 10.121

8.  Nutritional assessment with bioelectrical impedance analysis in maintenance hemodialysis patients.

Authors:  G M Chertow; E G Lowrie; D W Wilmore; J Gonzalez; N L Lew; J Ling; M S Leboff; M N Gottlieb; W Huang; B Zebrowski
Journal:  J Am Soc Nephrol       Date:  1995-07       Impact factor: 10.121

9.  Atrial natriuretic peptide in dialysis patients under various conditions of volume homeostasis.

Authors:  J Plum; B Grabensee
Journal:  J Intern Med       Date:  1991-03       Impact factor: 8.989

10.  Determinants of prescribed dialysis dose and survival in a cohort of chronic hemodialysis patients.

Authors:  Kunitoshi Iseki; Masahiko Tozawa; Shuichi Takishita
Journal:  Clin Exp Nephrol       Date:  2003-09       Impact factor: 2.801

View more
  4 in total

Review 1.  Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients.

Authors:  Connie M Rhee; Gregory A Brent; Csaba P Kovesdy; Offie P Soldin; Danh Nguyen; Matthew J Budoff; Steven M Brunelli; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2014-02-25       Impact factor: 5.992

2.  Prevalence and Clinical Significance of Low T3 Syndrome in Non-Dialysis Patients with Chronic Kidney Disease.

Authors:  Jingxian Fan; Peng Yan; Yingdeng Wang; Bo Shen; Feng Ding; Yingli Liu
Journal:  Med Sci Monit       Date:  2016-04-08

3.  Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.

Authors:  Takahiro Masuda; Takuya Murakami; Yusuke Igarashi; Kyochika Okabe; Takahisa Kobayashi; Shin-Ichi Takeda; Takako Saito; Chuji Sekiguchi; Yasuharu Miyazawa; Tetsu Akimoto; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

4.  The relationship between inflammatory factors, oxidative stress and DIO-1 concentration in patients with chronic renal failure accompanied with or without euthyroid sick syndrome.

Authors:  Shu-Lan Qin; Qi He; Ling Hu; Chun-Yan He; Li-Cheng Gao; Charlotte Aimee Young; Juan Chen; Cheng-Fang Jiang; Xiang-Feng Luo; Ying Zhou; Xia Sheng; Zhi-Hong Li; Mei-Ling Chen; Gaosi Xu
Journal:  J Int Med Res       Date:  2018-08-28       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.